Which of the following drug should not be used in a patient with renal failure?

NORCET -4 , 2023

Pharmacology

Medium

Appeared in: NORCET -4 , 2023

Explanation

Spironolactone is classified as a potassium-sparing diuretic.
Its mechanism involves blocking the action of aldosterone in the kidneys, which leads to sodium and water excretion but potassium retention.
Patients with renal failure have a compromised ability to excrete potassium, leading to a baseline risk of hyperkalemia (high blood potassium).
Administering a potassium-sparing diuretic like spironolactone to these patients severely increases the risk of life-threatening hyperkalemia, which can cause fatal cardiac arrhythmias.

Option B: Furosemide is a loop diuretic and is frequently used in patients with renal failure. It is effective at removing excess fluid (edema) even when the glomerular filtration rate (GFR) is low.
Option C: Sodium Bicarbonate is not a diuretic. It is an alkalinizing agent used to treat metabolic acidosis, a common complication of renal failure where the blood becomes too acidic.
Option D: Chlorthiazide is a thiazide diuretic. While thiazide diuretics become less effective as renal function declines (typically when GFR is less than 30 mL/min), they are not strictly contraindicated and do not pose the same immediate risk of severe hyperkalemia as spironolactone.

Visual 1: Table - Comparing different classes of diuretics (Loop, Thiazide, Potassium-sparing) showing their primary site of action in the nephron, key indications, and specific considerations in renal failure.
Visual 2: Flowchart - Illustrating the pathophysiology of hyperkalemia when a potassium-sparing diuretic is administered to a patient with chronic kidney disease.

Clinical Relevance

Nursing practice connection: Use the key finding related to Pharmacology: Contraindications of Diuretics in Renal Failure to guide bedside assessment, documentation, and the next nursing action.
Nurses must always review a patient's renal function (e.g., creatinine, eGFR) and recent electrolyte levels (especially potassium) before administering any diuretic, particularly potassium-sparing agents.
A key nursing responsibility is monitoring for signs of hyperkalemia, such as muscle weakness, fatigue, palpitations, and ECG changes (e.g., peaked T waves), in patients with renal impairment.
What if? If the patient had heart failure with preserved renal function, spironolactone might be indicated for its mortality benefits and to counteract potassium loss from loop diuretics. The presence of renal failure is the key factor that makes it contraindicated in this question.

How to Approach the Question

First, identify the core clinical condition in the question: 'renal failure'.
Recall the primary metabolic problem in renal failure, which is the impaired ability to excrete electrolytes, especially potassium.
Next, analyze the mechanism of action for each drug option provided.
Categorize each drug: Spironolactone (potassium-sparing diuretic), Furosemide (potassium-wasting loop diuretic), Sodium Bicarbonate (alkalinizing agent), and Chlorthiazide (potassium-wasting thiazide diuretic).
Evaluate which drug's action would dangerously compound the existing problem of renal failure. A drug that retains potassium is dangerous in a condition where potassium is already being retained.
Conclude that Spironolactone is the drug that should not be used due to the high risk of causing life-threatening hyperkalemia.

Concept Tested & Keywords

Concept Tested: Pharmacology: Contraindications of Diuretics in Renal Failure
Stem keywords: drug, renal failure
Lead-in keywords: not be used
Clinical cues: Patient condition: Renal failure, which implies impaired electrolyte excretion.
Negative lead-in flag: The question asks which drug should NOT be used, requiring identification of a contraindication.

q3mLJYT2bnDNeVFw-XeDP